The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects.

Rare Genitourinary Tumors offers the reader an up-to-date discussion of the less common neoplasms affecting the urinary tract and reproductive organs. Each authoritative chapter provides and in-depth discussion that is frequently not found in other urologic oncology textbooks. A valuable reference for urologists, oncologists, and those in specialty training, this volume provides ready access to information on etiology, incidence, risk factors, diagnosis, prognosis, insights from molecular pathology and, where applicable, data from clinical trials. The practical treatment guidelines included for each tumor type are written by experts and fully referenced.

Cancer and the Kidney covers the challenging overlap area of nephrology and oncology, both in terms of kidney problems in cancer patients, and cancer that affects kidney patients, including assessment of kidney function, to paraneoplastic disorders, acquired cysts and native kidney cancers, and all points inbetween.

Kidney Cancer: Principles and Practice is a comprehensive and interdisciplinary textbook that encompasses all clinically relevant aspects of the disease. This new edition has been extensively updated and includes brand new material covering the most recent developments in kidney cancer diagnosis and therapy. The user-friendly and clinically oriented content of the book guarantees that it will be of great interest to a wide range of medical professionals, and every effort has been made to ensure that contributions are both easy to understand and directly related to patient care. Content presentation departs from the usual dense chapter format featuring a lengthy series of paragraphs. Instead, each chapter contains several boxed sections, including one that summarizes essential "take home points" for the busy clinician and another that presents a patient-oriented case highlighting the clinical application of elements discussed in that chapter. In addition, accessible original images, illustrations, and diagrams (some in full color) are used to simplify particularly complex material. This book will be of value for clinicians, researchers, residents, fellows, students, and knowledgeable lay people. The contributors comprise an international group of authors with expertise in kidney cancer epidemiology, molecular biology, pathology, diagnosis, clinical features, staging, prognostic and predictive factors, surgery, systemic therapy, and emerging investigational approaches, among others.

Upper Urinary Tract Urothelial Carcinoma was at one time felt to be a somewhat rare entity. With the success of various treatments for bladder urothelial carcinoma, the incidence of this disease in the uretere and kidney is rising. Many medical subspecialists encounter these complex patients and a multimodality treatment plan is often required for care.

Prostate cancer is the commonest male cancer with over 5 million survivors in US alone. Worldwide, the problem is staggering and has attracted significant attention by media, scientists and cancer experts. Significant research, discoveries, innovations and advances in treatment of this cancer have produced voluminous literature which is difficult to synthesize and assimilate by the medical community. Prostate Cancer: A Comprehensive Perspective is a comprehensive and definitive source which neatly resolves this problem. It covers relevant literature by leading experts in basic science, molecular biology, epidemiology, cancer prevention, cellular imaging, staging, treatment, targeted therapeutics and innovative technologies. Prostate Cancer: A Comprehensive Perspective, is a valuable and timely resource for urologists and oncologists.

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.

This thoroughly updated and revised edition of a widely acclaimed book provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. The authors explain the trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting, and hereditary prostate cancer. Additional chapters reflect progress in the management of locally advanced disease, the use of nomograms to predict outcomes, the medical management of erectile dysfunction, brachytherapy, and deciding between surgery and radiation. A compact disk accompanies the book for downloading the book to a PC or PDA.